Can We Extend Beyond 2 Years of Adjuvant ALK TKI Established by ALINA and ELEVATE in Resected Early Stage ALK+ NSCLC a Disease with High Predilection for CNS Metastasis with Novel Clinical Trial Designs?
Lung Cancer: Targets and Therapy · 2026-09 · Volume 17 · 1-8
DOI: 10.2147/lctt.s642874 ↗Kurz gefasst
Fachartikel in der Zeitschrift Lung Cancer: Targets and Therapy, 2026-09. Verfasst von Vivian Thuy Tieu und 2 weiteren Autor:innen. Beteiligte Einrichtung: University of California Irvine School of Medicine, Department of Medicine, Orange, CA, 92602, USA. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- University of California Irvine School of Medicine, Department of Medicine, Orange, CA, 92602, USA.
ORCID-Profile: Misako Nagasaka, Sai-Hong Ignatius Ou
Zitieren
APA
Tieu, V. T., Nagasaka, M., & Ou, S. I. (2026). Can We Extend Beyond 2 Years of Adjuvant ALK TKI Established by ALINA and ELEVATE in Resected Early Stage ALK+ NSCLC a Disease with High Predilection for CNS Metastasis with Novel Clinical Trial Designs?. Lung Cancer: Targets and Therapy, Volume 17, 1-8. https://doi.org/10.2147/lctt.s642874
Vancouver
Tieu VT, Nagasaka M, Ou SI. Can We Extend Beyond 2 Years of Adjuvant ALK TKI Established by ALINA and ELEVATE in Resected Early Stage ALK+ NSCLC a Disease with High Predilection for CNS Metastasis with Novel Clinical Trial Designs?. Lung Cancer: Targets and Therapy. 2026;Volume 17:1-8. doi:10.2147/lctt.s642874
BibTeX
@article{Tieu2026,
author = {Tieu, Vivian Thuy and Nagasaka, Misako and Ou, Sai-Hong Ignatius},
title = {Can We Extend Beyond 2 Years of Adjuvant ALK TKI Established by ALINA and ELEVATE in Resected Early Stage ALK+ NSCLC a Disease with High Predilection for CNS Metastasis with Novel Clinical Trial Designs?},
journal = {Lung Cancer: Targets and Therapy},
year = {2026},
volume = {Volume 17},
pages = {1--8},
doi = {10.2147/lctt.s642874}
}
EUVIMED